disorder

(redirected from Myeloproliferative disorders)
Also found in: Dictionary, Thesaurus, Medical, Legal.

disorder

[dis′ȯrd·ər]
(crystallography)
Departures from regularity in the occupation of lattice sites in a crystal containing more than one element.
References in periodicals archive ?
Examination of blood smear is also important in patients with thrombocytosis to look for evidence of myeloproliferative disorder, such as giant platelets (Bain, 2005).
Myeloproliferative Disorders. Hematol Oncol Clin North Am 2017; 31(6):1029-1044.
Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008;205:585-94.
We report a severe NS phenotype with a horseshoe kidney, thrombocytopenia, myeloproliferative disorder (MPD), feeding difficulty secondary to pylorospasm, and respiratory failure with pulmonary capillaritis and vasculitis.
Protein C and S deficiency, antiphospolipid syndrome, myeloproliferative disorders, idiopathic hypereosinophilic syndrome, pheochromocytoma, and Takatsubo cardiomyopathy were reported to be related with thrombus formation in patients with a normal LV ejection fraction (8-10).
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet.
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.
A prospective evaluation of primary myeloproliferative disorders," Gastroenterology, vol.
It is associated with a multitude of conditions, including lymphoproliferative disorders (most common: 48%), myeloproliferative disorders (chronic granulocytic leukemia, essential thrombocythemia, and polycythemia vera), neoplasms (Wilms tumor), immunological disorders, cardiovascular diseases, hypothyroidism, hemoglobinopathies, drugs (valproate, ciprofloxacin, and hydroxyethyl starch), and infections [1, 2, 4-7].
Buser et al., "A gain-of-function mutation of JAK2 in myeloproliferative disorders," The New England Journal of Medicine, vol.
(4,5) They are rare tumors, with an incidence of 3 to 4.7% among myeloproliferative disorders, predominantly in AML.
Patients with other causes of thrombocytopenia (inherited thrombocytopenias), bone marrow failure syndromes, lymphoproliferative disorders, myeloproliferative disorders, thrombotic microangiopathies, megaloblastic anaemia and pseudothrombocytopenia were carefully excluded according to the findings in history, physical examination and investigations.